Altium Capital Management LP Affimed N.V. Transaction History

Altium Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $1.76 Million - $2.99 Million	900,000 New	900,000 $1.85 Million
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $3.57 Million - $4.7 Million	-665,000 Closed	0 $0
Q3 2021 Nov 17, 2021	BUY	$5.54 - $7.51 $57,316 - $77,698	10,346 Added 1.58%	665,000 $4.11 Million
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $3.63 Million - $4.92 Million	654,654 New	654,654 $4.28 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.